Erratum: Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency (Blood (2016) 128:1 (45-54) DOI: 10.1182/blood-2016-01-688226);Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency

Blood

Volumn 128, Issue 1, 2016, Pages 45-54

  Cicalese, Maria Pia ^a,b   Ferrua, Francesca ^a,c   Castagnaro, Laura ^a   Pajno, Roberta ^b,c   Barzaghi, Federica ^a,b   Giannelli, Stefania ^a   Dionisio, Francesca ^a   Brigida, Immacolata ^a   Bonopane, Marco ^a   Casiraghi, Miriam ^a,b   Tabucchi, Antonella ^d   Carlucci, Filippo ^d   Grunebaum, Eyal ^e   Adeli, Mehdi ^f   Bredius, Robbert G ^g   Puck, Jennifer M ^h   Stepensky, Polina ⁱ   Tezcan, Ilhan ^j   Rolfe, Katie ^k   De Boever, Erika ^k   Reinhardt, Rickey R ^k   Appleby, Jonathan ^k   Ciceri, Fabio ^b,c   Roncarolo, Maria Grazia ^a,c,l,m   Aiuti, Alessandro ^a,c   more..

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f HAMAD MEDICAL CORPORATION   (Qatar)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^j HACETTEPE UNIVERSITY   (Turkey)

^k GLAXOSMITHKLINE   (United Kingdom)

^l Department of Pediatrics   (United States)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BUSULFAN; CD34 ANTIGEN; IMMUNOGLOBULIN; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ANTIBODY RESPONSE; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CELL FRACTIONATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEVICE INFECTION; DRUG EFFICACY; DRUG SAFETY; ENZYME REPLACEMENT; EPSTEIN BARR VIRUS INFECTION; FATTY LIVER; FEMALE; FOLLOW UP; GASTROENTERITIS; GRANULOCYTE; GUILLAIN BARRE SYNDROME; HEARING IMPAIRMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGLOBULIN PRODUCTION; INFANT; LOW DRUG DOSE; LUNG MYCOSIS; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; NEUTROPENIA; OVERALL SURVIVAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHINITIS; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE SUBPOPULATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GENE THERAPY; AGAMMAGLOBULINEMIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONVALESCENCE; DEFICIENCY; DISEASE FREE SURVIVAL; GENE THERAPY; GENETICS; IMMUNOLOGY; MORTALITY; MULTICENTER STUDY; RETROVIRIDAE; SURVIVAL RATE;

ADENOSINE DEAMINASE; AGAMMAGLOBULINEMIA; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENETIC THERAPY; HUMANS; INFANT; MALE; RECOVERY OF FUNCTION; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; SURVIVAL RATE;

EID: 84977671730     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-05-782862     Document Type: Erratum

References (58)

1. Hirschhorn R. Immunodeficiency disease due to deficiency of adenosine deaminase. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases. New York, NY: Oxford University Press; 1999.
2. Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: An update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol. 2015;35(8):696-726.
3. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524-3532.
4. Bollinger ME, Arredondo-Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med. 1996;334(21):1367-1371.
5. Ryser O, Morell A, Hitzig WH. Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children. J Clin Immunol. 1988;8(6):479-485.
6. Yee A, De Ravin SS, Elliott E, Ziegler JB; Contributors to the Australian Paediatric Surveillance Unit. Severe combined immunodeficiency: A national surveillance study. Pediatr Allergy Immunol. 2008;19(4):298-302.
7. Verbsky JW, Baker MW, Grossman WJ, et al. Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol. 2012;32(1):82-88.
8. Vogel BH, Bonagura V, Weinberg GA, et al. Newborn screening for SCID in New York State: Experience from the first two years. J Clin Immunol. 2014;34(3):289-303.
9. Hirschhorn R, Grunebaum E, Roifman C, Candotti F. Immunodeficiency due to defects of purine metabolism. In: Ochs HD, Smith CIE, Puck JM, eds. Primary immunodeficiency diseases: A molecular and genetic approach. New York, New York: Oxford University Press; 2014 [3rd edition].
10. Hassan A, Booth C, Brightwell A, et al; Inborn Errors Working Party of the European Group for Blood and Marrow Transplantation and European Society for Immunodeficiency. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17): 3615-3624, quiz 3626.
11. Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316(10):589-596.
12. Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency: An update after 8.5 years. Clin Immunol Immunopathol. 1995;76(3 Pt 2):S228-S232.
13. Weinberg K, Hershfield MS, Bastian J, et al. T lymphocyte ontogeny in adenosine deaminasedeficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase. J Clin Invest. 1993;92(2): 596-602.
14. Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133-143.
15. Baffelli R, Notarangelo LD, Imberti L, et al. Diagnosis, treatment, and long-term follow-up of patients with ADA deficiency: A single-center experience. J Clin Immunol. 2015;35(7):624-637.
16. Aiuti A, Slavin S, Aker M, et al. Correction of ADASCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002; 296(5577):2410-2413.
17. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-458.
18. Selleri S, Brigida I, Casiraghi M, et al. In vivo T-cell dynamics during immune reconstitution after hematopoietic stem cell gene therapy in adenosine deaminase severe combined immune deficiency. J Allergy Clin Immunol. 2011;127(6): 1368-758.
19. Bartelink IH, Bredius RGM, Belitser SV, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):231-241.
20. Pierre Fabre Médicament. Busilvex [summary of product characteristics]. 2014. Available at: Www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000472/WC500052066.pdf. Accessed September 1, 2015.
21. Carlucci F, Tabucchi A, Aiuti A, et al. Capillary electrophoresis in diagnosis and monitoring of adenosine deaminase deficiency. Clin Chem. 2003;49(11):1830-1838.
22. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest. 1981;68(6):1387-1393.
23. Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr. 2001;139(1):44-50.
24. Ochs HD, Buckley RH, Kobayashi RH, et al. Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood. 1992;80(5):1163-1171.
25. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. 2007;123(2):139-147.
26. Comans-Bitter WM, de Groot R, van den Beemd R, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr. 1997;130(3):388-393.
27. Shearer WT, Rosenblatt HM, Gelman RS, et al; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: The Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol. 2003; 112(5):973-980.
28. Kruisbeek AM, Shevach E, Thornton AM. Proliferative assays for T cell function. Curr Protoc Immunol. 2004;Chapter 3:Unit 3.12.
29. Aiuti A, Biasco L, Scaramuzza S, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science. 2013; 341(6148):1233151.
30. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for- Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development. Geneva: World Health Organization; 2006.
31. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: Head Circumference-for-Age, Arm Circumference-for- Age, Triceps Skinfold-for-Age, and Subscapular Skinfold-for-Age: Methods And Development. Geneva: World Health Organization; 2007.
32. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med. 1998; 17(4):407-429.
33. Brigida I, Sauer AV, Ferrua F, et al. B-cell development and functions and therapeutic options in adenosine deaminase-deficient patients. J Allergy Clin Immunol. 2014;133(3): 799-80610.
34. Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD341 cells in ADA-deficient SCID neonates. Nat Med. 1998; 4(7):775-780.
35. Gaspar HB. Bone marrow transplantation and alternatives for adenosine deaminase deficiency. Immunol Allergy Clin North Am. 2010;30(2): 221-236.
36. Hay AD, Heron J, Ness A; ALSPAC study team. The prevalence of symptoms and consultations in pre-school children in the Avon Longitudinal Study of Parents and Children (ALSPAC): A prospective cohort study. Fam Pract. 2005;22(4):367-374.
37. Grunebaum E, Chung CT, Dadi H, et al. Purine metabolism, immune reconstitution, and abdominal adipose tumor after gene therapy for adenosine deaminase deficiency. J Allergy Clin Immunol. 2011;127(6):1417-9.e3.
38. Biasco L, Ambrosi A, Pellin D, et al. Integration profile of retroviral vector in gene therapy treated patients is cell-specific according to gene expression and chromatin conformation of target cell. EMBO Mol Med. 2011;3(2):89-101.
39. Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3(97):97ra80.
40. Hönig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood. 2007; 109(8):3595-3602.
41. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
42. Buckley RH, Win CM, Moser BK, Parrott RE, Sajaroff E, Sarzotti-Kelsoe M. Posttransplantation B cell function in different molecular types of SCID. J Clin Immunol. 2013; 33(1):96-110.
43. Cicalese MP, Aiuti A. Clinical applications of gene therapy for primary immunodeficiencies. Hum Gene Ther. 2015;26(4):210-219.
44. Cavazzana-Calvo M, Fischer A, Hacein-Bey- Abina S, Aiuti A. Gene therapy for primary immunodeficiencies: part 1. Curr Opin Immunol. 2012;24(5):580-584.
45. Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M. Gene therapy for primary immunodeficiencies: Part 2. Curr Opin Immunol. 2012;24(5):585-591.
46. Siler U, Paruzynski A, Holtgreve-Grez H, et al. Successful combination of sequential gene therapy and rescue allo-HSCT in two children with X-CGD-importance of timing. Curr Gene Ther. 2015;15(4):416-427.
47. Grez M, Reichenbach J, Schwäble J, Seger R, Dinauer MC, Thrasher AJ. Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol Ther. 2011;19(1):28-35.
48. Braun CJ, Boztug K, Paruzynski A, et al. Gene therapy for Wiskott-Aldrich syndrome: long-term efficacy and genotoxicity. Sci Transl Med. 2014; 6(227):227ra33.
49. Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120(18):3635-3646.
50. Mukherjee S, Thrasher AJ. Gene therapy for PIDs: progress, pitfalls and prospects. Gene. 2013;525(2):174-181.
51. Knight S, Collins M, Takeuchi Y. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther. 2013;13(3):211-227.
52. Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117(8): 2233-2240.
53. Chaffee S, Mary A, Stiehm ER, Girault D, Fischer A, Hershfield MS. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest. 1992;89(5):1643-1651.
54. Chun JD, Lee N, Kobayashi RH, Chaffee S, Hershfield MS, Stiehm ER. Suppression of an antibody to adenosine-deaminase (ADA) in an ADA-deficient patient receiving polyethylene glycol modified adenosine deaminase. Ann Allergy. 1993;70(6):462-466.
55. Lainka E, Hershfield MS, Santisteban I, et al. polyethylene glycol-conjugated adenosine deaminase (ADA) therapy provides temporary immune reconstitution to a child with delayedonset ADA deficiency. Clin Diagn Lab Immunol. 2005;12(7):861-866.
56. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol. 2012;3:265.
57. Rivers L, Gaspar HB. Severe combined immunodeficiency: Recent developments and guidance on clinical management. Arch Dis Child. 2015;100(7):667-672.
58. Gaspar B, Buckland K, Rivat C, et al. Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency [abstract]. J Clin Immunol. 2014;34 suppl 2:S167. Abstract ESID-0018.